About kyowa kirin - KYKOF
Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.
KYKOF At a Glance
Kyowa Kirin Co., Ltd.
Otemachi Financial City Grand Cube
Tokyo, Tokyo 100-0004
| Phone | 81-3-5205-7200 | Revenue | 3.15B | |
| Industry | Pharmaceuticals: Major | Net Income | 577.39M | |
| Sector | Health Technology | 2023 Sales Growth | 3.838% | |
| Fiscal Year-end | 12 / 2024 | Employees | 5,974 | |
| View SEC Filings |
KYKOF Valuation
| P/E Current | 14.374 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 15.651 |
| Price to Sales Ratio | 2.874 |
| Price to Book Ratio | 1.523 |
| Price to Cash Flow Ratio | 10.998 |
| Enterprise Value to EBITDA | 7.637 |
| Enterprise Value to Sales | 2.019 |
| Total Debt to Enterprise Value | 0.027 |
KYKOF Efficiency
| Revenue/Employee | 526,454.336 |
| Income Per Employee | 96,649.899 |
| Receivables Turnover | 3.723 |
| Total Asset Turnover | 0.437 |
KYKOF Liquidity
| Current Ratio | 4.587 |
| Quick Ratio | 4.051 |
| Cash Ratio | 3.025 |
KYKOF Profitability
| Gross Margin | 72.50 |
| Operating Margin | 21.672 |
| Pretax Margin | 21.777 |
| Net Margin | 18.359 |
| Return on Assets | 8.019 |
| Return on Equity | 9.858 |
| Return on Total Capital | 9.458 |
| Return on Invested Capital | 9.654 |
KYKOF Capital Structure
| Total Debt to Total Equity | 2.899 |
| Total Debt to Total Capital | 2.817 |
| Total Debt to Total Assets | 2.363 |
| Long-Term Debt to Equity | 1.926 |
| Long-Term Debt to Total Capital | 1.872 |